Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 11/20 | 0.57 |
| ▸ | BCHE | P06276 | 10/20 | 0.56 |
| ▸ | BACE1 | P56817 | 9/20 | 0.56 |
| ▸ | CCR3 | P51677 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | HRH1 | P35367 | 1/20 | 0.50 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14093043 | 1.00 | ACHE (0.57) | ACHEBCHEBACE1CCR3CYP1A2 | |
| SCHEMBL19223406 | 0.90 | CYP2D6 (0.60) | ACHEBCHEBACE1CYP1A2CYP3A4 | |
| SCHEMBL22623856 | 0.90 | CYP2D6 (0.60) | ACHEBCHEBACE1CYP1A2CYP3A4 | |
| SCHEMBL12385776 | 0.90 | CYP2D6 (0.60) | ACHEBCHEBACE1CYP1A2CYP3A4 | |
| SCHEMBL10236431 | 0.90 | ACHE (0.66) | ACHEBCHEBACE1CCR3HRH1 | |
| SCHEMBL2485710 | 0.87 | HRH1 (0.55) | ACHEBCHEBACE1CCR3CYP1A2 | |
| SCHEMBL607896 | 0.87 | ACHE (0.54) | ACHEBCHEBACE1CCR3CYP1A2 | |
| SCHEMBL3272029 | 0.87 | ACHE (0.54) | ACHEBCHEBACE1CCR3CYP1A2 | |
| SCHEMBL607895 | 0.87 | ACHE (0.54) | ACHEBCHEBACE1CCR3CYP1A2 | |
| SCHEMBL12384414 | 0.86 | FUCA1 (0.55) | ACHEBCHEBACE1SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190233441-A1 | TRIAZOLOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2019-08-01 | — | — | US | disclosed |
| US-20180086757-A1 | TRIAZOLOPYRIDINE COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2018-03-29 | — | — | US | disclosed |
| US-20180086757-A1 | TRIAZOLOPYRIDINE COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2018-03-29 | — | — | US | disclosed |
| US-20160185780-A1 | TRIAZOLOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2016-06-30 | — | — | US | disclosed |
| CN-104583194-A | Pyridazine and pyridine derivatives as NAMPT inhibitors | ABBVIE INC | 2015-04-29 | — | — | CN | disclosed |
| US-8623893-B2 | Pyridino-pyridinone derivatives, preparation and therapeutic use thereof | SANOFI (FR) | 2014-01-07 | — | — | US | disclosed |
| US-8461328-B2 | Tricyclic heterocyclic compounds, compositions and methods of use thereof | GENENTECH, INC. (US) | 2013-06-11 | — | — | US | disclosed |
| US-20130005724-A1 | PYRIDINO-PYRIDINONE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2013-01-03 | — | — | US | disclosed |
| US-8309552-B2 | Immunomodulating heterocyclic compounds | MEDIGENE AG (DE) | 2012-11-13 | — | — | US | disclosed |
| US-20110201593-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2011-08-18 | — | — | US | disclosed |
| US-7358373-B2 | Cathepsin K inhibitors | ROCHE PALO ALTO LLC (US) | 2008-04-15 | — | — | US | disclosed |
| US-20080045527-A1 | Immunomodulating Heterocyclic Compounds | MEDIGENE LIMITED (GB) | 2008-02-21 | — | — | US | disclosed |
| EP-1864986-A1 | PYRAZOLOPYRIMIDINE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | Teijin Pharma Limited (JP) | 2007-12-12 | — | — | EP | disclosed |
| US-7276505-B2 | Immunomodulating heterocyclic compounds | MEDIGENE LIMITED (GB) | 2007-10-02 | — | — | US | disclosed |
| US-7276505-B2 | Immunomodulating heterocyclic compounds | MEDIGENE LIMITED (GB) | 2007-10-02 | — | — | US | disclosed |
| US-20070173519-A1 | Pyrazolopyrimidine derivatives or pharmaceutically acceptable salts thereof | TEIJIN PHARMA LIMITED | 2007-07-26 | — | — | US | disclosed |
| US-20070173519-A1 | Pyrazolopyrimidine derivatives or pharmaceutically acceptable salts thereof | TEIJIN PHARMA LIMITED | 2007-07-26 | — | — | US | disclosed |
| US-20070032484-A1 | Cathepsin K inhibitors | ROCHE PALO ALTO LLC | 2007-02-08 | — | — | US | disclosed |
| US-20070021428-A1 | Immunomodulating heterocyclic compounds | AVIDEX LIMITED (GB) | 2007-01-25 | — | — | US | disclosed |
| US-20070021428-A1 | Immunomodulating heterocyclic compounds | AVIDEX LIMITED (GB) | 2007-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130005724-A1 | PYRIDINO-PYRIDINONE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | PDGFRB, FLT3, PDGFRA | ACHE 4039/4885BCHE 4275/4885BACE1 3267/4885 |
| US-20160185780-A1 | TRIAZOLOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | ABL1, JAK2, JAK1 | ACHE 2310/4885BCHE 3460/4885BACE1 3734/4885 |
| US-20070032484-A1 | Cathepsin K inhibitors | CTSK, CTSS, CTSF | ACHE 2120/4885BCHE 2588/4885BACE1 146/4885 |
| US-20070173519-A1 | Pyrazolopyrimidine derivatives or pharmaceutically acceptable salts thereof | MAPKAPK2, MAPKAPK5, MAPKAPK3 | ACHE 4471/4885BCHE 4878/4885BACE1 4384/4885 |
| US-20110201593-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | CCNY, CCNA1, CCNA2 | ACHE 3858/4885BCHE 2929/4885BACE1 3655/4885 |
| US-20190233441-A1 | TRIAZOLOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | ABL1, JAK2, JAK1 | ACHE 2310/4885BCHE 3460/4885BACE1 3734/4885 |
| US-20080045527-A1 | Immunomodulating Heterocyclic Compounds | CD40, CD40LG, NGFR | ACHE 3369/4885BCHE 3194/4885BACE1 2391/4885 |
| US-20180086757-A1 | TRIAZOLOPYRIDINE COMPOUNDS AND METHODS OF USE THEREOF | JAK1, JAK2, JAK3 | ACHE 4012/4885BCHE 4553/4885BACE1 4126/4885 |
| US-20070021428-A1 | Immunomodulating heterocyclic compounds | CD40, CD40LG, NGFR | ACHE 3264/4885BCHE 3003/4885BACE1 2269/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.